Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

U. Klinkhardt · SciRah

Researcher profile · Semantic Scholar

U. Klinkhardt

Share profile

U. Klinkhardt — researcher profile on SciRah

h-index: 19
Works: 49
Citations: 1,577

Most-cited papers

Clopidogrel but not aspirin reduces P‐selectin expression and formation of platelet‐leukocyte aggregates in patients with atherosclerotic vascular disease *
U. Klinkhardt, R. Bauersachs, Jan Adams, J. Graff +2 more
2003Clinical pharmacology and therapy212 citations
Semantic Scholar
Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer
A. Papachristofilou, M. Hipp, U. Klinkhardt, M. Früh +23 more
2019Journal of Immunotherapy for Cancer199 citations Open access
Semantic Scholar
Avoidance of Bleeding During Surgery in Patients Receiving Anticoagulant and/or Antiplatelet Therapy
S. Harder, U. Klinkhardt, J. Alvarez
2004Clinical Pharmacokinetics142 citations
Semantic Scholar
Clopidogrel, but not abciximab, reduces platelet leukocyte conjugates and P‐selectin expression in a human ex vivo in vitro model
U. Klinkhardt, J. Graff, S. Harder
2002Clinical pharmacology and therapy112 citations
Semantic Scholar
Treatment outcome according to tumor RAS mutation status in OPUS study patients with metastatic colorectal cancer (mCRC) randomized to FOLFOX4 with/without cetuximab.
C. Bokemeyer, C. Köhne, F. Ciardiello, H. Lenz +5 more
2014111 citations
Semantic Scholar
Angiotensin II infusion increases plasma erythropoietin levels via an angiotensin II type 1 receptor-dependent pathway.
J. Gossmann, Ralf Burkhardt, S. Harder, T. Lenz +4 more
2001Kidney International109 citations Open access
Semantic Scholar
Transition from argatroban to oral anticoagulation with phenprocoumon or acenocoumarol: effects on prothrombin time, activated partial thromboplastin time, and Ecarin Clotting Time
S. Harder, J. Graff, U. Klinkhardt, N. von Hentig +4 more
2004Thrombosis and Haemostasis64 citations
Semantic Scholar
Effects of selective COX‐2 inhibition on prostanoids and platelet physiology in young healthy volunteers
J. Graff, C. Skarke, U. Klinkhardt, B. Watzer +4 more
2007Journal of Thrombosis and Haemostasis58 citations Open access
Semantic Scholar
Close relationship between the platelet activation marker CD62 and the granular release of platelet-derived growth factor.
J. Graff, U. Klinkhardt, V. Schini-Kerth, S. Harder +3 more
2002Journal of Pharmacology and Experimental Therapeutics58 citations
Semantic Scholar
Ex vivo–in vitro interaction between aspirin, clopidogrel, and the glycoprotein IIb/IIIa inhibitors abciximab and SR121566A
U. Klinkhardt, Carl M. Kirchmaier, D. Westrup, J. Graff +3 more
2000Clinical pharmacology and therapy40 citations
Semantic Scholar
The CX3C chemokine fractalkine mediates platelet adhesion via the von Willebrand receptor glycoprotein Ib.
S. Meyer dos Santos, U. Klinkhardt, K. Scholich, K. Nelson +5 more
2011Blood38 citations Open access
Semantic Scholar
1149PResults of the randomized, placebo-controlled phase I/IIB trial of CV9104, an mRNA based cancer immunotherapy, in patients with metastatic castration-resistant prostate cancer (mCRPC)
A. Stenzl, S. Feyerabend, I. Syndikus, T. Sarosiek +16 more
201737 citations Open access
Semantic Scholar
Effects of antiplatelet agents on platelet-induced thrombin generation.
W. Wegert, J. Graff, D. Kaiser, H. Breddin +2 more
2002International journal of clinical pharmacology and therapeutics36 citations
Semantic Scholar
A novel μ-fluidic whole blood coagulation assay based on Rayleigh surface-acoustic waves as a point-of-care method to detect anticoagulants.
S. Meyer dos Santos, A. Zorn, Z. Guttenberg, B. Picard-Willems +4 more
2013Biomicrofluidics35 citations Open access
Semantic Scholar
In vitro dose response to different GPIIb/IIIa-antagonists: inter-laboratory comparison of various platelet function tests.
S. Harder, U. Klinkhardt, J. Graff, D. Westrup +7 more
2001Thrombosis Research30 citations
Semantic Scholar
Using ImageJ for the quantitative analysis of flow-based adhesion assays in real-time under physiologic flow conditions
S. Meyer dos Santos, U. Klinkhardt, R. Schneppenheim, S. Harder
2010Platelets28 citations
Semantic Scholar
Induction of central signalling pathways and select functional effects in human platelets by β‐boswellic acid
Daniel Poeckel, L. Tausch, Anja Altmann, Christian Feisst +4 more
2005British Journal of Pharmacology28 citations Open access
Semantic Scholar
Immunosuppressive therapy regimen and platelet activation in renal transplant patients
J. Graff, U. Klinkhardt, S. Harder, W. Wegert +3 more
2002Clinical pharmacology and therapy28 citations
Semantic Scholar
Platelet-leucocyte adhesion markers before and after the initiation of antiretroviral therapy with HIV protease inhibitors.
N. von Hentig, Ann-Kristin Förster, Karina Kuczka, U. Klinkhardt +5 more
2008Journal of Antimicrobial Chemotherapy24 citations
Semantic Scholar
Flow cytometric measurement of platelet-leukocyte aggregates: a possible target to monitor platelet function?
U. Klinkhardt, S. Harder
2005Seminars in Thrombosis and Hemostasis19 citations
Semantic Scholar
31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two
C. Ager, M. Reilley, C. Nicholas, Todd Bartkowiak +496 more
2016Journal for ImmunoTherapy of Cancer18 citations Open access
Semantic Scholar
Pharmacodynamic profile of antiplatelet agents: marked differences between single versus costimulation with platelet activators.
J. Graff, U. Klinkhardt, S. Harder
2004Thrombosis Research17 citations
Semantic Scholar
Thrombolytics
S. Harder, U. Klinkhardt
2000Drug Safety17 citations
Semantic Scholar
Effects of the NHE-1 inhibitor cariporide alone or together with the P2Y12 antagonist AR-C 69331 MX on CD62p expression and formation of platelet-leukocyte aggregates.
U. Klinkhardt, Karina Kuczka, S. Harder
2003Thrombosis Research16 citations
Semantic Scholar
Anticoagulation With Argatroban for Elective Percutaneous Coronary Intervention: Population Pharmacokinetics and Pharmacokinetic‐Pharmacodynamic Relationship of Coagulation Parameters
K. Akimoto, U. Klinkhardt, A. Zeiher, Margit Niethammer +1 more
2011Journal of clinical pharmacology13 citations
Semantic Scholar
Abstract CT217: Phase I, first-in-human trial evaluating BI 1387446 (STING agonist) alone and in combination with ezabenlimab (BI 754091; anti-PD-1) in solid tumors
K. Harrington, E. Parkes, J. Weiss, M. Ingham +6 more
2021Clinical Trials11 citations
Semantic Scholar
Pharmacodynamic characterization of the interaction between abciximab or tirofiban with unfractionated or a low molecular weight heparin in healthy subjects.
U. Klinkhardt, J. Graff, D. Westrup, Carl M. Kirchmaier +3 more
2001British Journal of Clinical Pharmacology11 citations Open access
Semantic Scholar
Effect of angiotensin II infusion with and without angiotensin II type 1 receptor blockade on nitric oxide metabolism and endothelin in human beings: A placebo‐controlled study in healthy volunteers
J. Gossmann, Ralf Burkhardt, S. Harder, T. Lenz +5 more
2000Clinical pharmacology and therapy10 citations
Semantic Scholar
The integrin antagonist, cilengitide, is a weak inhibitor of αIIbβ3 mediated platelet activation and inhibits platelet adhesion under flow
S. Meyer dos Santos, Karina Kuczka, B. Picard-Willems, K. Nelson +2 more
2015Platelets8 citations
Semantic Scholar
Pharmacodynamic characterization of the interaction between the glycoprotein IIb/IIIa inhibitor YM337 and unfractionated heparin and aspirin in humans.
J. Graff, U. Klinkhardt, D. Westrup, C. Kirchmaier +2 more
2003British Journal of Clinical Pharmacology7 citations Open access
Semantic Scholar
408 Phase I, first-in-human trial evaluating BI 1387446 (stimulator of interferon genes [STING] agonist) alone and combined with BI 754091 (anti-programmed cell death [PD]-1) in solid tumors
K. Harrington, E. Parkes, J. Weiss, M. Ingham +7 more
2020Journal for ImmunoTherapy of Cancer6 citations Open access
Semantic Scholar
P-selectin (CD62p) and P-selectin glycoprotein ligand-1 (PSGL-1) polymorphisms: minor phenotypic differences in the formation of platelet-leukocyte aggregates and response to clopidogrel.
U. Klinkhardt, I. Dragutinović, S. Harder
2005International journal of clinical pharmacology and therapeutics6 citations
Semantic Scholar
Adhesion, spreading, and aggregation of platelets in flowing blood and the reliability of the retention test Homburg.
B. Krischek, E. Morgenstern, P. Mestres, U. Klinkhardt +7 more
2005Seminars in Thrombosis and Hemostasis6 citations
Semantic Scholar
Abstract 4522: Potent induction of a tumor-specific immune response by a cyclic dinucleotide STING agonist
G. Gremel, M. Impagnatiello, Sebastian Carotta, Otmar Schaaf +17 more
2020Immunology5 citations
Semantic Scholar
Phase I dose-escalation and expansion study of intratumoral CV8102, a RNA-based TLR- and RIG-1 agonist in patients with advanced solid tumors.
P. Terheyden, C. Weishaupt, L. Heinzerling, U. Klinkhardt +11 more
2018Annals of Oncology4 citations Open access
Semantic Scholar
Abstract LB-021: Intratumoral RNA-based TLR-7/-8 and RIG-I agonist CV8102 alone and in combination with anti-PD-1 in a Phase I dose-escalation and expansion trial in patients with advanced solid tumors
T. Eigentler, J. Krauss, J. Schreiber, C. Weishaupt +18 more
2019Clinical research3 citations
Semantic Scholar
Role of the retention test Homburg in evaluating platelet hyperactivity and in monitoring therapy with antiplatelet drugs.
B. Krischek, W. Brannath, U. Klinkhardt, J. Graff +6 more
2005Seminars in Thrombosis and Hemostasis3 citations
Semantic Scholar
Phase Ib trial of the RNActive cancer vaccine BI 1361849 (CV9202) and local radiotherapy (RT) in patients (pts) with stage IV NSCLC with disease control after 1st-line chemotherapy or during therapy with an EGFR-TKI: results of an interim analysis.
M. Sebastian, U. Klinkhardt
20162 citations
Semantic Scholar
MS523 USING ImageJ FOR THE QUANTITATIVE ANALYSIS OF FLOW-BASED ADHESION ASSAYS IN REAL-TIME UNDER PHYSIOLOGIC FLOW CONDITIONS
S. Meyer dos Santos, U. Klinkhardt, R. Schneppenheim, S. Harder
20102 citations
Semantic Scholar
Ex vivo/In vitro Interaction between ASA, Clopidogrel and GPIIb/IIIa-Inhibitors
C. Kirchmaier, D. Westrup, J. Graff, R. Mahnel +3 more
19992 citations
Semantic Scholar
P3.02c-091 Final Phase Ib Results of RNActive® Cancer Vaccine BI 1361849 and Local Radiation as Maintenance Therapy for Stage IV NSCLC
A. Papachristofilou, M. Sebastian, C. Weiss, M. Früh +22 more
20171 citations Open access
Semantic Scholar
Phenotypic differences of human neutrophils of carriers of the PSGL-1 A and B-allele in binding to immobilised P-selectin under flow conditions.
S. Meyer dos Santos, U. Klinkhardt, K. Lang, Jeannine Parisius +2 more
2011Thrombosis Research1 citations
Semantic Scholar
A phase I dose-escalation and expansion trial of intratumorally administered CV8102, alone and in combination with anti-PD-1 in patients with advanced solid tumours
J. Krauss, T. Eigentler, J. Schreiber, C. Weishaupt +16 more
2019Annals of Oncology0 citations Open access
Semantic Scholar
1155PResults of an open label randomized phase II trial of CV9104, an mRNA-based multivalent cancer immunotherapy in patients (pts) with intermediate or high risk localized prostate cancer (PC) undergoing radical prostatectomy (RPE)
A. Stenzl, S. Feyerabend, H. Kübler, M. Retz +14 more
20170 citations Open access
Semantic Scholar
MS524 PHENOTYPIC DIFFERENCES OF HUMAN NEUTROPHILS OF CARRIERS OF THE PSGL-1 A AND B-ALLELE IN BINDING TO P-SELECTIN UNDER FLOW CONDITIONS
S. Meyer dos Santos, U. Klinkhardt, K. Lang, Jeannine Parisius +2 more
20100 citations
Semantic Scholar
P402 THE CX3C CHEMOKINE FRACTALKINE AND GPIbα MEDIATE PLATELET TRANSLOCATION ON VON WILLEBRAND FACTOR UNDER PHYSIOLOGIC FLOW CONDITIONS
S. Meyer dos Santos, U. Klinkhardt, K. Scholich, Karina Kuczka +1 more
20100 citations
Semantic Scholar
[Dose-response relationship: relevance for medical practice].
U. Klinkhardt, S. Harder
2000Medizinische Klinik0 citations
Semantic Scholar
[Dose-response relation: relevance for clinical practice].
U. Klinkhardt, S. Harder
1998Medizinische Klinik0 citations
Semantic Scholar
Conditions of deformation of the expiratory flow curve in obstructive lung disease.
J. Meier-Sydow, U. Cegla, R. Dierkesmann, E. Huegel +3 more
1971Bulletin de physio-pathologie respiratoire0 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

S. Harder×28
Invite
S. Harder — researcher profile on SciRah
J. Graff×16
Invite
J. Graff — researcher profile on SciRah
S. Meyer dos Santos×8
Invite
S. Meyer dos Santos — researcher profile on SciRah
U. Gnad-Vogt×7
Invite
U. Gnad-Vogt — researcher profile on SciRah

×7

Invite

Karina Kuczka — researcher profile on SciRah

Invite

T. Seibel — researcher profile on SciRah

Invite

B. Scheel — researcher profile on SciRah

Invite

D. Westrup — researcher profile on SciRah

Invite

S. Koch — researcher profile on SciRah

C. Kirchmaier×4

Invite

C. Kirchmaier — researcher profile on SciRah

Invite

M. Hipp — researcher profile on SciRah

M. Sebastian×3

Invite

M. Sebastian — researcher profile on SciRah